Internal Development Pipeline

Our broad internal clinical and pre-clinical pipeline focuses on ADCs and checkpoint regulators and targets patients with solid tumors who respond poorly to PD-1 inhibitors. 

​

Program	Program Summary	Indications	Molecule Class
OBT076	Our lead asset, OBT076, is an innovative Antibody Drug Conjugate (ADC) with a potential dual mechanism of action.   OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients. The CD205 receptor is highly overexpressed in solid and liquid tumors with high unmet need including gastric, lung and ovarian cancer.   OBT076 is demonstrating activity as a monotherapy. In addition, OBT076 can also act as a ‘primer’ re-engaging the patient’s immune system while at the same time targeting cancer cells.   A maximum tolerated dose has been determined for OBT076 and the asset has shown promising early signs of clinical activity. It is currently being evaluated in Phase 1b expansion cohorts in multiple solid tumor indications. OBT is also planning combination trials for OBT076.   OBT is responsible for the full development, approval and commercialization of OBT076 in North America and Japan. For oncology indications outside these territories OBT has out-licensed OBT076 to Menarini. Click here for Clinical Trials information.	​Recurrent and metastatic gastric, lung and ovarian cancer and Her minus HR positive breast cancer.	ADC
OBT698	OBT698 (click here for accompanying audio) is a unique immuno-modulatory receptor highly expressed in tumor infiltrating lymphocytes (TILs) of ten different solid tumor types and in activated T cells.   OBT has developed a first-in-class humanized antibody directed against the human extracellular domain of OBT698 antigen. It shows a strong agonistic effect to activated CD8+ T cells – promoting their proliferation, cytokine secretion, and cytolytic ability – and suppresses Treg function.   The antitumor activity of OBT698 is demonstrated by enhancement of cytotoxicity towards tumor cells. OBT698 antibody therapy as a single agent will be investigated in a Phase I clinical study in patients across a range of solid tumors, especially in human cancers that show the presence of TILs. OBT698 now progressing towards an IND.	Solid tumors	IO mAB
OBT698/PDL1	Bispecific combining the novel immune-checkpoint regulator, OBT698 with a PDL1 antibody in a single molecule.	​Solid tumors	IO/bispecific
OBT700/PDL1	T cell engagement of tumor cells in vitro and in patients leads to simultaneous down regulation of the OBT700 ligand and upregulation of PDL1. We have developed a bispecific molecule combining our OBT700 agonist activity with a PDL1 antagonist.	​Solid tumors	IO/bispecific
5 ADC Programs	Novel ADC targets overexpressed in multiple solid tumors with next-generation linker payload technologies.	​Solid tumors	ADC

 ADC: Antibody Drug Conjugate
IO: Immuno-oncology
mAB: Monoclonal Antibody